Related Experiment Video

Updated: May 22, 2026

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

Behavioral symptoms in mild cognitive impairment as compared with Alzheimer's disease and healthy older adults

Stefan Van der Mussele1, Nathalie Le Bastard, Yannick Vermeiren

  • 1Reference Center for Biological Markers of Dementia (BIODEM), Laboratory of Neurochemistry and Behavior, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.

International Journal of Geriatric Psychiatry
|May 3, 2012
PubMed
Abstract

Insights

Mild cognitive impairment (MCI) patients exhibit behavioral symptoms that are intermediate between normal aging and Alzheimer's disease (AD). These findings characterize MCI as a distinct transitional state, with ongoing research exploring its predictive value for dementia progression.

Area of Science:

  • Neuroscience
  • Gerontology
  • Psychiatry

Background:

  • Mild cognitive impairment (MCI) represents a transitional phase between normal aging and dementia.
  • Understanding behavioral differences in MCI is crucial for early diagnosis and intervention.
  • This study compares behavioral profiles of MCI, Alzheimer's disease (AD), and healthy older adults.

Purpose of the Study:

  • To characterize the behavioral symptoms present in individuals with MCI.
  • To compare the behavioral profiles of MCI patients with those of AD patients and healthy controls.
  • To establish MCI's behavioral characteristics as an intermediate state.

Main Methods:

  • Cross-sectional analysis of baseline data from a longitudinal study.
  • Inclusion of 270 MCI patients, 402 AD patients, and 108 healthy controls.
  • Utilized standardized behavioral assessment scales: Middelheim Frontality Score, BPSD, CMAI, and Cornell Scale.

Main Results:

  • Moderate-to-severe behavioral symptoms were observed in 13% of MCI patients, versus 39% in AD and 3% in controls.
  • MCI patients displayed an intermediate severity of behavioral symptoms compared to controls and AD.
  • Key symptoms in MCI included aggressiveness, affective disturbance, and anxiety, with frontal lobe symptoms also intermediate.

Conclusions:

  • MCI patients exhibit a behavioral profile that is intermediate between normal aging and AD.
  • Behavioral disturbances in MCI may serve as predictors for the progression to dementia.
  • Further longitudinal follow-up is essential to validate these findings.

More Related Videos

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

Digital Handwriting Analysis of Characters in Chinese Patients with Mild Cognitive Impairment05:58

Digital Handwriting Analysis of Characters in Chinese Patients with Mild Cognitive Impairment

Published on: March 11, 2021

Related Concept Videos

Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...